Chanda Sanjay, Chief Development Officer at AN2 Therapeutics, Inc. ($ANTX), made two open market sales of company shares in the last year, totaling just over $9,300. The most recent sale occurred on January 6, 2026. These sales rank 11,285th among 11,678 individual insiders in our database, where the average is about $8.6 million across roughly six transactions per insider. Sanjay reported no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | D | Stock Option (right to buy) | 57950 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.19% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Stock Option (right to buy) | 41665 | $0.00 | 41,665.0000 | 30,276,230 | 9999.99% | 0.14% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | D | Stock Option (right to buy) | 41665 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.14% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Stock Option (right to buy) | 66000 | $0.00 | 66,000.0000 | 30,276,230 | 9999.99% | 0.22% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | D | Stock Option (right to buy) | 66000 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.22% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Stock Option (right to buy) | 57950 | $0.00 | 57,950.0000 | 30,276,230 | 9999.99% | 0.19% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Common Stock | 38000 | $0.00 | 118,823.0000 | 30,276,230 | 47.02% | 0.13% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Stock Option (right to buy) | 77000 | $0.00 | 77,000.0000 | 30,276,230 | 9999.99% | 0.25% |
| Jan. 6, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | S | Common Stock | 5956 | $1.01 | 75,823.0000 | 30,276,230 | 7.28% | 0.02% |
| Jan. 5, 2026 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | S | Common Stock | 3295 | $1.00 | 81,779.0000 | 30,276,230 | 3.87% | 0.01% |
| Feb. 26, 2025 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Common Stock | 50250 | $0.00 | 80,074.0000 | 29,828,227 | 168.49% | 0.17% |
| Feb. 26, 2025 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Stock Option (right to buy) | 100500 | $0.00 | 100,500.0000 | 29,828,227 | 9999.99% | 0.34% |
| Jan. 3, 2025 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | S | Common Stock | 2957 | $1.34 | 29,824.0000 | 29,828,227 | 9.02% | 0.01% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Common Stock | 27500 | $0.00 | 28,235.0000 | 23,600,107 | 3741.50% | 0.12% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Common Stock | 27500 | $0.00 | 28,235.0000 | 23,600,107 | 3741.50% | 0.12% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Stock Option (right to buy) | 55000 | $0.00 | 55,000.0000 | 23,600,107 | 9999.99% | 0.23% |
| Feb. 15, 2023 | AN2 Therapeutics, Inc. | $ANTX | Chanda Sanjay | Chief Development Officer | A | Stock Option (right to buy) | 57950 | $0.00 | 57,950.0000 | 0 | 9999.99% | 0.00% |